- Home
- PHUN vs VIGL Comparison
PHUN vs VIGL Comparison
Compare PHUN & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHUN
- VIGL
- Stock Information
- Founded
- PHUN 2009
- VIGL 2020
- Country
- PHUN United States
- VIGL United States
- Employees
- PHUN N/A
- VIGL N/A
- Industry
- PHUN EDP Services
- VIGL Biotechnology: Pharmaceutical Preparations
- Sector
- PHUN Technology
- VIGL Health Care
- Exchange
- PHUN Nasdaq
- VIGL Nasdaq
- Market Cap
- PHUN 64.1M
- VIGL 134.9M
- IPO Year
- PHUN N/A
- VIGL 2022
- Fundamental
- Price
- PHUN $3.29
- VIGL $8.05
- Analyst Decision
- PHUN Buy
- VIGL Buy
- Analyst Count
- PHUN 2
- VIGL 7
- Target Price
- PHUN $7.75
- VIGL $8.00
- AVG Volume (30 Days)
- PHUN 282.3K
- VIGL 1.1M
- Earning Date
- PHUN 08-07-2025
- VIGL 08-12-2025
- Dividend Yield
- PHUN N/A
- VIGL N/A
- EPS Growth
- PHUN N/A
- VIGL N/A
- EPS
- PHUN N/A
- VIGL N/A
- Revenue
- PHUN $2,956,000.00
- VIGL N/A
- Revenue This Year
- PHUN $3.01
- VIGL N/A
- Revenue Next Year
- PHUN $50.72
- VIGL N/A
- P/E Ratio
- PHUN N/A
- VIGL N/A
- Revenue Growth
- PHUN N/A
- VIGL N/A
- 52 Week Low
- PHUN $2.22
- VIGL $1.31
- 52 Week High
- PHUN $14.60
- VIGL $8.06
- Technical
- Relative Strength Index (RSI)
- PHUN 52.92
- VIGL 88.18
- Support Level
- PHUN $3.25
- VIGL $7.86
- Resistance Level
- PHUN $3.56
- VIGL $8.05
- Average True Range (ATR)
- PHUN 0.18
- VIGL 0.02
- MACD
- PHUN 0.01
- VIGL -0.15
- Stochastic Oscillator
- PHUN 61.97
- VIGL 73.15
About PHUN Phunware Inc.
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States. The company has two reportable segments: Software subscriptions and services; and Advertising. It derives maximum revenue from Software subscriptions and services.
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a clinical-stage biotechnology company engaged in improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. Microglia are the sentinel immune cells of the brain and play a critical role in maintaining central nervous system (CNS) health and responding to damage caused by disease. The group provides solutions for fully human monoclonal antibody and Oral small molecule TERM2 agonist.